3[1]JOHN B,MC CRAN MD.Prevention of unfavorable scars using early pulsed dyelaser treatment:a preliminary report Ann[J].Plast Surg,1999,42(1):7-14.
4[2]EHRCICH HP.Hgpertrophic Scar:an interruption in the remodeling of repaire Laser Doppler blood flow study[J].Plast Reconstr Sury, 1998,90(6):993-998.
5[3]VEDA K,FURUGA E,YASUDA Y,et al.Hypertrophic scars have continous high metabotic activity[J].PLAST,RECONSTR,SURG,1999,104(3):674-678.
6[4]BEE TW,BALSWIN HC,GODDARD JR,et al.Angiogentsis in pathological and surgical scar[J].Hum Pathol,1998,29(11):1273-1278.
7史鸿涛 金东明 史力.消积排通汤治疗蟹足肿[J].吉林中医药,1998,12(1):5-5.
8Yang GP, Lim IJ, Phan TT, et al. From scarless fetal wounds to keloids:molecular studies in wound healing. Wound Repair Regen 2003; 11 (6): 411-8
9Phan TT, Lim IJ, Chan SY, et al. Suppression of transforming growth factor beta/smad signaling in keloid-derived fibroblasts by quercetin: implications for thetreatment of excessive scars. J Trauma 2004; 57(5): 1032 -7
10Matou S, Colliec-Jouault S, Galy-Fauroux I, et al. Effect of an oversulfated exopolysaccharide on angiogenesis induced by fibroblast growth factor-2 or vascular endothelial growth factor in vitro. Biochem Pharmacol 2005; 69 (5): 751 -9
4YANG J Y, HUANG Chunyuan. The effect combined steroid and calcium channel blocker injection on human hypertrophic scars in animal model: a new strategy for the treatment of hypertrophic scars[J]. Dermatol Surg, 2010, 36(12): 1942-1949.
5ATKINS S, SMITH K G, LOESCHERA R, et al. Scarring impedes regeneration at sites of peripheral nerve repair[J]. NeuroReport, 2006, 17(12): 1245-1249.
6MUSTOE T A, COOTER R D, GOLD M H, et al. International clinical recommendations on scar management[J]. Plast Reconstr Surg, 2002, 110(2): 560-571.
7ZHU K Q, ENGRAV L H. Changes in VEGF and nitricoxide after deep dermal injury in the female, red Duroc pig-further similarities between female, Duroc scar and human hypertrophic scar[J]. Bums, 2005, 31(1): 5.
8MAAS R, SCHWEDHELM E, ALBSMEIER J, et al. The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function[J]. Vasc Med, 2002, 7(3): 213-225.
9SHARIF M R, SHAANANI A, MAHMOUDI H, et al. Association of the serum vascular endothelial growth factor levels with benign prostate hyperplasia and prostate malignancies[J]. Nephro Urol Moil, 2014, 6(3): e14778.
10HOLLINGSWORTH H C, KOHN E C, STEINBERG S M, et al. Tumor angiogenesis in advanced stage ovarian carcinoma[J]. Am J Pathol, 1995, 147(1): 33--41.
